EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers

Jiajun Ye, Shu Yang, Yu Liu, Zhiyong Quan, Mingru Zhang, Guiyu Li, Zifan Zhu, Jia Wang, Taoqi Ma, Junlin Wang, Zhibo Liu, Jing Wang und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-11 · 52 (13) · 4939-4951

DOI: 10.1007/s00259-025-07362-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.05.2025. Verfasst von Jiajun Ye und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. Hauptthemen laut MEDLINE: Membrane Proteins, Gelatinases, Serine Endopeptidases, Radiopharmaceuticals. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Shaanxi Province Key Industry Innovation Chain, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Fibroblast activation protein (FAP) has emerged as one of the most promising theranostic targets. FT-FAPI, a potential FAP-targeted probe with enhanced tumor-targeting ability using an organotrifluoroborate linker, was verified for the biological effect in cell and animal experiments in previous work. However, the differences in pharmacokinetic profiles, biodistribution and dosimetry of FT-FAPI under multiple nuclides labeling in animals and humans is unclear. In this study, we sought to explore the discrepancies in the performance of FT-FAPI after labeling with different radioisotopes and to compare 68Ga-FT-FAPI with 68Ga-FAPI-04 in healthy volunteers. METHODS: Preparation and quality control of 18F-/68Ga-/177Lu-FT-FAPI injections were conducted. Biodistribution studies were performed in mice and pharmacokinetic analysis were performed using blood samples. 18F-FT-FAPI and 68Ga-FT-FAPI were initially tested in normal volunteers, respectively. Further, 68Ga-FT-FAPI was scanned at multiple time points for 1 h dynamic, 2 h and 3 h static imaging, and compared with 68Ga-FAPI-04 to clarify the distribution patterns and excretion parameters. Radiation dosimetry was estimated based on the uptake of the probes in organs of mice or humans, respectively. RESULTS: 18F-/68Ga-/177Lu-FT-FAPI showed high safety and tolerability in mice or humans. The pharmacokinetic characteristics of FT-FAPI in mice and humans best fit a two-compartment model. In mice, the results of biodistribution showed that the clearance half-life (T1/2β) of FT-FAPI varied with different labeled radionuclides, with 68Ga-FT-FAPI having the shortest T1/2β of 26.1 min. In HT-1080-FAP tumor-bearing mice, 177Lu-FT-FAPI showed higher tumor uptake and longer retention time than 177Lu-FAPI-04, which implies a higher radiation dose in the tumor. In healthy volunteers, both 18F-FAPI-04 and 68Ga-FT-FAPI were metabolized by the kidneys and excreted through the urinary system. The uptake of 68Ga-FT-FAPI in most normal tissues was similar to that of 68Ga-FAPI-04, being higher only in the sublingual gland, thyroid gland and pancreas. 68Ga-FT-FAPI had similar T1/2β (75.0 min vs. 77.2 min) and a slightly higher effective dose (ED) (12.4 ± 1.51 µSv·MBq-1 vs. 9.99 ± 1.85 µSv·MBq-1) compared to 68Ga-FAPI-04. Compared to 68Ga-FT-FAPI, 18F-FT-FAPI has slightly higher liver and bone uptake, especially in the delayed time points. CONCLUSION: The pharmacokinetics of FT-FPAI varies depending on the labeled nuclide. Compared to 177Lu-FAPI-04, 177Lu-FT-FAPI showed higher tumor uptake and longer retention time. In healthy volunteers, 68Ga-FT-FAPI had lower renal uptake and higher sublingual gland, thyroid gland and pancreas uptake at 1 h p.i. than that of 68Ga-FAPI-04, with no significant differences in other organs. Further optimization will be conducted for the radiolabeling process of 18F-FT-FAPI to evaluate its diagnostic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsGelatinasesSerine EndopeptidasesRadiopharmaceuticalsAnimalsMiceHumansHealthy VolunteersTissue DistributionMaleFemaleGallium RadioisotopesAdultLutetiumRadioisotopesRadioactive TracersIsotope LabelingFluorine RadioisotopesEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

DosimetryFT-FAPIFibroblast activation proteinOrganotrifluoroborateTheranostics

Substanzen

Membrane ProteinsGelatinasesSerine EndopeptidasesGallium RadioisotopesLutetiumRadioisotopesRadiopharmaceuticalsRadioactive TracersFluorine RadioisotopesEndopeptidases

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
  • Peking University-Tsinghua University Center for Life Sciences, Peking University, Beijing, 100871, China.
  • Peking University-Tsinghua University Center for Life Sciences, Peking University, Beijing, 100871, China. zbliu@pku.edu.cn.
  • Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education…
  • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. 13909245902@163.com.
  • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. fmmukf@qq.com.

Förderung

  • Shaanxi Province Key Industry Innovation Chain
  • National Natural Science Foundation of China

Zitieren

APA

Ye, J., Yang, S., Liu, Y., Quan, Z., Zhang, M., Li, G., Zhu, Z., Wang, J., Ma, T., Wang, J., Liu, Z., Wang, J., & Kang, F. (2025). Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 52(13), 4939-4951. https://doi.org/10.1007/s00259-025-07362-4

Vancouver

Ye J, Yang S, Liu Y, Quan Z, Zhang M, Li G, et al. Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(13):4939-4951. doi:10.1007/s00259-025-07362-4

BibTeX
@article{Ye2025,
  author = {Ye, Jiajun and Yang, Shu and Liu, Yu and Quan, Zhiyong and Zhang, Mingru and Li, Guiyu and Zhu, Zifan and Wang, Jia and Ma, Taoqi and Wang, Junlin and Liu, Zhibo and Wang, Jing and Kang, Fei},
  title = {Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {13},
  pages = {4939--4951},
  doi = {10.1007/s00259-025-07362-4}
}
Kostenlos starten →